PDE5A and pulmonary arterial hypertension: We included randomized control trials (RCTs) in which PDE5 inhibitors were compared to a placebo or any other treatment in adults with pulmonary hypertension from any cause, irrespective of the World Health Organization (WHO) functional class and group of pulmonary hypertension.